Universität zu Köln

Wuerstlein, R., Kates, R., Gluz, O., Grischke, E. M., Schem, C., Thill, M., Hasmueller, S., Koehler, A., Otremba, B., Griesinger, F., Schindlbeck, C., Trojan, A., Otto, F., Knauer, M., Pusch, R. and Harbeck, N. (2019). Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Breast Cancer Res. Treat., 175 (2). S. 389 - 400. NEW YORK: SPRINGER. ISSN 1573-7217

Full text not available from this repository.

Abstract

PurposeThe WSG-PRIMe Study prospectively evaluated the impact of the 70-gene signature MammaPrint (R) (MP) and the 80-gene molecular subtyping assay BluePrint (R) on clinical therapy decisions in luminal early breast cancer.Methods452 hormone receptor (HR)-positive and HER2-negative patients were recruited (N0, N1). Physicians provided initial therapy recommendations based on clinicopathological factors. After prospective risk classification by MammaPrint/BluePrint was revealed, post-test treatment recommendations and actual treatment were recorded. Decisional Conflict and anxiety were measured by questionnaires.ResultsPost-test switch (in chemotherapy (CT) recommendation) occurred in 29.1% of cases. Overall, physician adherence to MP risk assessment was 92.3% for low-risk and 94.3% for high-risk MP scores. Adherence was remarkably high in discordant groups: 74.7% of physicians initially recommending CT switched to CT omission following low-risk MP scores; conversely, 88.9% of physicians initially recommending CT omission switched to CT recommendations following high-risk MP scores. Most patients (99.2%) recommended to forgo CT post-test and 21.3% of patients with post-test CT recommendations did not undergo CT; among MP low-risk patients with pre-test and post-test CT recommendations, 40% did not actually undergo CT. Luminal subtype assessment by BluePrint was discordant with IHC assessment in 34% of patients. Patients' State Anxiety scores improved significantly overall, particularly in MP low-risk patients. Trait Anxiety scores increased slightly in MP high risk and decreased slightly in MP low-risk patients.ConclusionsMammaPrint and BluePrint test results strongly impacted physicians' therapy decisions in luminal EBC with up to three involved lymph nodes. The high adherence to genetically determined risk assessment represents a key prerequisite for achieving a personalized cost-effective approach to disease management of early breast cancer.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wuerstlein, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kates, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gluz, O. UNSPECIFIED UNSPECIFIED UNSPECIFIED Grischke, E. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schem, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thill, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hasmueller, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Koehler, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Otremba, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Griesinger, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schindlbeck, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Trojan, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Otto, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Knauer, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pusch, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Harbeck, N. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-147057
DOI:	10.1007/s10549-018-05075-x
Journal or Publication Title:	Breast Cancer Res. Treat.
Volume:	175
Number:	2
Page Range:	S. 389 - 400
Date:	2019
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1573-7217
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language 70-GENE PROGNOSIS-SIGNATURE; CLINICAL UTILITY; VALIDATION; THERAPY; PROFILE; WOMEN Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14705